September 5th 2023
The experimental gene therapy was administered as a treatment in part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.
ASRS 2023: Clearside Biomedical’s suprachoroidal injection platform taking stage in Seattle
July 30th 2023According to Clearside Biomedical, a pair of presentations at the ASRS annual meeting in Seattle highlight CLS-AX as a potential treatment option for wet AMD treatment with a new mechanism of action and the possibility for longer duration of effect than current therapies.
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapies in Neovascular AMD and DME
May 12th 2023Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, provide an overview of the effect of anti-VEGF treatment in neovascular age-related macular degeneration and diabetic macular edema.
ARVO 2023: Nonclinical data by Adverum Biotechnologies regarding potential treatment of wet AMD
April 24th 2023Adverum Biotechnologies Inc. shared nonclinical data at ARVO 2023 in New Orleans that staggered, bilateral administration of Ixo-vec in NHPs was well tolerated with encouraging therapeutic activity and no signals of increased inflammation.